Iterum Therapeutics Showcases Innovations at Investment Conference
Iterum Therapeutics to Make a Mark at Global Investment Conference
Iterum Therapeutics plc (Nasdaq: ITRM), based in Dublin, Ireland and Chicago, is a prominent clinical-stage pharmaceutical company that specializes in the development of next-generation oral antibiotics. These innovative solutions aim to tackle infections caused by multi-drug resistant pathogens in community settings. In a recent announcement, Corey Fishman, the CEO of Iterum, shared exciting news regarding their participation in the 26th Annual H.C. Wainwright Global Investment Conference.
Event Details and Presentation Timing
The prestigious conference is set to take place from September 9 to September 11, 2024, at the elegant Lotte New York Palace Hotel. Iterum is scheduled for a presentation on September 10 at 8:30 am ET, during which they will discuss their advancements and future strategies. Additionally, management will offer one-on-one meetings for interested investors on the same day.
Access and Availability
Participation in the H.C. Wainwright conference is designated for qualified investors. For those unable to attend in person, a webcast of the presentation will be made available shortly afterward on Iterum’s website in the Events & Presentations section.
Commitment to Combatting Antibiotic Resistance
Iterum Therapeutics is committed to addressing the escalating global crisis of multi-drug resistant pathogens. The company is actively developing differentiated anti-infectives that aim to significantly improve health outcomes for individuals facing serious infections. Their flagship product, sulopenem, is a novel penem anti-infective with both oral and intravenous formulations.
Innovative Product Pipeline
Sulopenem has shown potent in vitro activity against numerous strains of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Iterum is currently navigating the regulatory landscape, having submitted a New Drug Application (NDA) for oral sulopenem aimed at treating uncomplicated urinary tract infections in adult women. This application has been accepted for review by the U.S. Food and Drug Administration (FDA).
Regulatory Designations and Acknowledgments
In recognition of its potential, sulopenem has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for seven distinct indications. These designations not only highlight the urgency of addressing antibiotic resistance but also facilitate the development and review process for drugs that demonstrate promise in treating serious infections.
Contact Information for Interested Parties
Investors or interested parties looking to connect with Iterum Therapeutics can reach out to Judy Matthews, the Chief Financial Officer, at 312-778-6073 or via email. The company encourages inquiries as it aims to engage with stakeholders and provide further information regarding its innovative work in the pharmaceutical field.
Frequently Asked Questions
What is the focus of Iterum Therapeutics?
Iterum Therapeutics primarily focuses on developing new oral antibiotics to combat multi-drug resistant infections.
When will Iterum present at the H.C. Wainwright Conference?
Iterum's presentation is scheduled for September 10, 2024, at 8:30 am ET.
What product is Iterum currently working on?
Iterum is advancing sulopenem, a novel anti-infective candidate designed to treat infections resistant to other antibiotics.
What regulatory designations has sulopenem received?
Sulopenem has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.
Who can attend the H.C. Wainwright Conference?
The conference is open to qualified investors interested in the latest advancements in the pharmaceutical industry.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Investors Mobilize for Starbucks Corporation Securities Fraud
- Potential Class Action for Sprinklr Investors amid Allegations
- AI Innovations Boosting Agrochemicals Market Growth Trends
- Celebrating Creativity: The 7th Annual Beef Tallow Fry Contest
- Northern Illinois Food Bank's Initiatives to Combat Hunger
- US State Investments in Defense Arms to Aid Ukraine
- Icing Detector Activations Reported in Voepass Plane Crash
- Super Micro Computer's Stock Decline: What's Behind It?
- The Incredible Growth of Your $100 Investment in CBRE Group
- What a $1000 Investment in Vistra Looks Like Today
Recent Articles
- ORIC Pharmaceuticals Grants Stock Options to New Employees
- NewAmsterdam Pharma Boosts Staff with Incentive Stock Options
- Investors Can Join Class Action Against Arbor Realty Trust
- Investors Can Join Class Action Against DexCom, Inc. for Fraud
- U.S. Court to Hear Xockets' Antitrust Case Against Nvidia Soon
- Liebherr Launches Innovative Freestanding Bottom Freezers
- Exploring Recent Options Trends at Palo Alto Networks
- Insightful Options Movement in Newmont Mining Stock
- Exploring the Options Strategies of Dollar General Investors
- Key Cannabis Stock Performers Highlighted for Early September
- Nike Sees Increased Bullish Options Activity Amid Market Trends
- Understanding Recent Options Trends for Chevron (CVX)
- An In-Depth Analysis of Intuit's Options Trading Strategies
- American Healthcare REIT Announces Quarterly Distribution Update
- Exploring Alliant Energy's Recent Short Selling Trends
- Understanding Old National's Shift in Short Interest Dynamics
- Nvidia Faces Challenges: But Is This a Buying Chance?
- Analyzing Legend Biotech's Short Interest Trends and Insights
- Unlocking the Value of a Decade-Long Investment in DECK
- Exploring the Growth of $100 in S&P Global Over a Decade
- Transforming $1000 into Wealth via O'Reilly Automotive Growth
- Transforming $100 Into Over $1000: The ELV Journey
- Cansortium Takes Strategic Steps for Financial Flexibility
- Market Fluctuations: Fed Rate Cuts and Semiconductor Struggles
- ARS Pharmaceuticals (NASDAQ: SPRY) Receives Positive Rating Update
- Why Sylvamo Corporation (SLVM) is a Momentum Investment Pick
- Discover Why Phibro Animal Health is Powering Forward Strongly
- Why Investing in International Flavors (IFF) is Smart Now
- Elutia Marks a Transformative Year of Milestones and Growth
- HTD Unveils Exciting New Furniture Collections for the Market
- American Healthcare REIT Announces Q3 2024 Cash Distribution
- MPLX LP Plans to Release Q3 Financial Results Shortly
- Marathon Petroleum Corp. Prepares for Third-Quarter Report
- Huntington Expands Commercial Banking with New Mortgage Sector
- Swiss Helvetia Fund Announces $0.129 Quarterly Distribution
- Market Downtime: Job Data Sparks Concerns for Investors
- Former American Airlines Mechanic Sentenced for Drug Smuggling
- Market Fluctuations Amid Rising Unemployment in the US
- Bunzl's Upgrade Signals Strong Investment Potential
- California's New Hemp Regulations: Industry Concerns Unveiled
- Investing Insights: Limbach's Upgrade to Strong Buy Status
- Sony's PS5 Price Hike: What This Means for Gamers Worldwide
- Lennar Recognized Among Top Workplaces in Southern California
- Investigation Opportunity for Transocean Ltd. Shareholders
- Membrane Separation Technology Market Growth to Reach $90.6B
- Precipio's Strategy to Reprice Employee Stock Options
- Revolutionizing Spinal Cord Injury Recovery with ExoPTEN
- Senseonics to Showcase Innovative Diabetes Tech at Conference
- Freshpet, Inc. Welcomes New COO with Inducement Grant
- Apellis Pharmaceuticals Issues Equity Awards to New Hire